Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TRIMEBUTINE MALEATE

All products: not a benefit

Other products in the same Health Canada class (A03A) — coverage varies; not interchangeable

  • Glycopyrrolate (Sandoz Glycopyrrolate): limited Use 481, Not a benefit

Mint-Trimebutine · DIN 02538210 · 200mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Trimebutine · DIN 02538210 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-03-28 Health Canada: Marketed since 2024-01-17 · brand MINT-TRIMEBUTINE · ATC A03AA05 TRIMEBUTINE · form Tablet · route Oral · ingredients TRIMEBUTINE MALEATE 200 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Trimebutine: Formulary list price $0.7677/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7677 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102696 · Verify on the e-Formulary ↗ (DIN 02538210)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02538210). DIN 02538210: Mint-Trimebutine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 120800061; group id 213; item number 0387; lccId None; manufacturer id MIN Source form: Tab; strength: 200mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.7677; ministry $0.7677 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538210 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102696
Interchangeable products
Apo-Trimebutine · DIN 02245664 · $0.7677 Modulon · DIN 00803499 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered

Matched class: 12:08 Parasympatholytic (Cholinergic Blocking) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM Some products covered without a code (check the product listing): IPRATROPIUM BROMIDE, OXYBUTYNIN CHLORIDE, TRIHEXYPHENIDYL HCL 12:08 Parasympatholytic (Cholinergic Blocking) Agents

ACLIDINIUM BROMIDE

· 1 products · General benefit · strengths: 400mcg/actuation · Pd Inh-60 Dose Pk

BENZTROPINE MESYLATE

· 1 products · General benefit · strengths: 1mg · Tab

ETHOPROPAZINE HCL

· 1 products · General benefit · strengths: 50mg · Tab

GLYCOPYRRONIUM BROMIDE

· 1 products · General benefit · strengths: 50mcg · Inh Pd-Cap

IPRATROPIUM BROMIDE

· 12 products · Listed, not a benefit (3), Limited Use, codes 256, 257, 258, 259 (3), Limited Use, codes 265, 266, 267, 268 (4), General benefit (2) · strengths: 250mcg/mL, 125mcg/mL, 20mcg/Metered Dose · Inh Sol-20mL Pk, Inh Sol-2mL UDV Pk, Inh-200 Dose Pk

OXYBUTYNIN CHLORIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1mg/mL, 5mg · O/L, Tab

PROCYCLIDINE HCL

· 1 products · General benefit · strengths: 2.5mg · Tab

TRIHEXYPHENIDYL HCL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 2mg, 5mg · Tab

HYOSCINE BUTYLBROMIDE

· 2 products · Limited Use, codes 481 · strengths: 10mg · Tab

IPRATROPIUM BROMIDE/SALBUTAMOL

· 3 products · Listed, not a benefit (1), Limited Use, codes 256, 257, 258, 259 (2) · strengths: 500mcg/2.5mg/2.5mL · Inh Sol-2.5mL Amp Pk

SCOPOLAMINE HYDROBROMIDE

· 4 products · Listed, not a benefit (2), Limited Use, codes 481 (2) · strengths: 0.4mg/mL, 0.6mg/mL · Inj Sol (Preservative Free)

FLAVOXATE HCL

· 2 products · Listed, not a benefit · strengths: 200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:08 and 5 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE APO-TRIMEBUTINE (trimebutine maleate) is indicated: – for the treatment and relief of symptoms associated with the irritable bowel syndrome (spastic colon), and – in postoperative paralytic ileus in order to accelerate the resumption of the intestinal transit following abdominal surgery. https://pdf.hres.ca/dpd_pm/00074927.PDF PM date: MAR 14, 2024 Source product: APO-TRIMEBUTINE; DIN 02245663; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Mint-Trimebutine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026